Renaissance Capital logo

YS Biopharma (Summit Healthcare Acquisition) Priced, Nasdaq: YS

Blank check company targeting a healthcare business with a strong China nexus (completed 3/16/2023).

Industry: SPAC

First Day Return: 0.0%

Industry: SPAC

We are a newly incorporated blank check company. Bo Tan, our Chief Executive Officer and Co-Chief Investment Officer, has over 20 years of extensive experience in the financial and pharmaceutical industries and was the President and Chief Financial Officer of 3S Bio. Ken Poon, our President and Co-Chief Investment Officer, has nearly 30 years of capital markets experiences in Asia and is the founding partner of XCap Partners Limited, a boutique advisory firm in Hong Kong. We intend to focus on potential acquisition targets in the healthcare industry. While we may acquire a business in any region globally, we will focus on finding an asset with a strong China nexus. We believe the healthcare sector in Asia has historically benefited from the in-licensing of novel or differentiated therapies to address critical unmet medical needs in Greater China and other emerging Asia Pacific markets. Today, we are witnessing the rise of healthcare out-licensing from China, a phenomenon that creates a 'two-way' traffic that brings significant benefits to patients in both China and Western countries. Our management team has demonstrated a strong track record of creating significant shareholder values at healthcare companies across the various stages of development. Leveraging on our broad network, deep industry insights, exceptional operational expertise and proven deal execution, we believe our team has the relevant skills and experiences to generate significant shareholder value.
more less
IPO Data
IPO File Date 05/03/2021
Offer Price $10.00
Price Range $10.00 - $10.00
Offer Shares (mm) 20.0
Deal Size ($mm) $200
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 06/08/2021
Offer Price IPO Intelligence Only
Price Range IPO Intelligence Only
Offer Shares (mm) IPO Intelligence Only
Deal Size ($mm) $200
Lock-Up Date IPO Intelligence Only
Street Research IPO Intelligence Only
Underwriters
IPO Intelligence Only
Company Data
Headquarters Hong Kong, China
Founded 2020
Employees at IPO 2

YS Biopharma (Summit Healthcare Acquisition) (YS) Performance